Wall Street equity research analysts generally lean toward a consensus Buy rating for TG Therapeutics (NASDAQ: TGTX), driven by strong commercial adoption of its flagship multiple sclerosis treatment, Briumvi, and an expanding clinical pipeline. While a majority of covering analysts recommend strong buys or buys, a small percentage suggest holding or selling due to valuation debates and portfolio concentration risks, leaving investors to weigh commercial growth against near-term biotech market volatility.